Evidence map›Paper›PMID 30410442›Full record

ReviewFrontiers in pharmacology2018

Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin.

Jingyao Zhang, Yun Chen, Huiqin Luo, Linlin Sun, Mengting Xu, Jin Yu, Qigang Zhou, Guoliang Meng, Shengju Yang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review of the Composition and Antimicrobial Roles of Extracts of Vine Tea (Ampelopsis grossedentata).Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingyao ZhangDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
Yun ChenDepartment of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong, China.
Huiqin LuoDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
Linlin SunDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
Mengting XuDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
Jin YuDepartment of Pharmacology, School of Pharmacy, Key Laboratory of Inflammation and Molecular Drug Target of Jiangsu Province, Nantong University, Nantong, China.
Qigang ZhouDepartment of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Guoliang MengDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
Shengju YangDepartment of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the most abundant natural flavonoid in rattan tea, dihydromyricetin (DMY) has shown a wide range of pharmacological effects. In addition to the general characteristics of flavonoids, DMY has the effects of cardioprotection, anti-diabetes, hepatoprotection, neuroprotection, anti-tumor, and dermatoprotection. DMY was also applied for the treatment of bacterial infection, osteoporosis, asthma, kidney injury, nephrotoxicity and so on. These effects to some extent enrich the understanding about the role of DMY in disease prevention and therapy. However, to date, we still have no outlined knowledge about the detailed mechanism of DMY, which might be related to anti-oxidation and anti-inflammation. And the detailed mechanisms may be associated with several different molecules involved in cellular apoptosis, oxidative stress, and inflammation, such as AMP-activated protein kinase (AMPK), mitogen-activated protein kinase (MAPK), protein kinase B (Akt), nuclear factor-κB (NF-κB), nuclear factor E2-related factor 2 (Nrf2), ATP-binding cassette transporter A1 (ABCA1), peroxisome proliferator-activated receptor-γ (PPARγ) and so on. Here, we summarized the current pharmacological developments of DMY as well as possible mechanisms, aiming to push the understanding about the protective role of DMY as well as its preclinical assessment of novel application.

Indexed as

apoptosiscardioprotectiondihydromyricetinhepatoprotectionneuroprotectionoxidative stress

Identifiers

PMID30410442
PMCPMC6209623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.